The New Strategy for Pharmacological Treatment in People With Schizophrenia
NCT ID: NCT00352339
Last Updated: 2009-08-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
90 participants
INTERVENTIONAL
2006-08-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia
NCT00283179
Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia Patients
NCT03839251
Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up
NCT02532491
Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia
NCT00202007
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up
NCT03883204
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Aripiprazole
switching group (from risperidone to aripiprazole)
Rispridoen and Aripiprazole
Start with risperidone and switch it to aripiprazole. Flexible dose
Risperidone
Start with risperidone and keep it through the end of study
Risperidne
Start with risperidne and keep it through the end of study. Risperidne:flexible dose
Abilify
Start with aripiprazole and keep it through the end of study
Abilify
Start with abilify and keep it through the end of study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Risperidne
Start with risperidne and keep it through the end of study. Risperidne:flexible dose
Abilify
Start with abilify and keep it through the end of study
Rispridoen and Aripiprazole
Start with risperidone and switch it to aripiprazole. Flexible dose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Acute phase
Exclusion Criteria
* Substance Abuse
* High risk for suicide
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Inje University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Clinical Trial Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joo-Cheol Shim, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Clinical Trial Center, Paik hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dongrae Hospital
Busan, , South Korea
Dongseo Hospital
Masan, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Aripiprazole study 2006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.